JP2023505219A5 - - Google Patents
Info
- Publication number
- JP2023505219A5 JP2023505219A5 JP2022533416A JP2022533416A JP2023505219A5 JP 2023505219 A5 JP2023505219 A5 JP 2023505219A5 JP 2022533416 A JP2022533416 A JP 2022533416A JP 2022533416 A JP2022533416 A JP 2022533416A JP 2023505219 A5 JP2023505219 A5 JP 2023505219A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- individual
- amino acid
- acid sequence
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025106921A JP2025138745A (ja) | 2019-12-06 | 2025-06-25 | 再発性および／または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962944809P | 2019-12-06 | 2019-12-06 | |
| US62/944,809 | 2019-12-06 | ||
| EP20315186.5 | 2020-04-17 | ||
| EP20315186 | 2020-04-17 | ||
| US202063023198P | 2020-05-11 | 2020-05-11 | |
| US63/023,198 | 2020-05-11 | ||
| US202063037353P | 2020-06-10 | 2020-06-10 | |
| US63/037,353 | 2020-06-10 | ||
| US202063094833P | 2020-10-21 | 2020-10-21 | |
| US63/094,833 | 2020-10-21 | ||
| PCT/US2020/063468 WO2021113754A1 (en) | 2019-12-06 | 2020-12-04 | Use of isatuximab for the treatment of relapsed and/or refractory multiple myeloma |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025106921A Division JP2025138745A (ja) | 2019-12-06 | 2025-06-25 | 再発性および／または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023505219A JP2023505219A (ja) | 2023-02-08 |
| JP2023505219A5 true JP2023505219A5 (https=) | 2023-12-08 |
| JP7704751B2 JP7704751B2 (ja) | 2025-07-08 |
Family
ID=74046182
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022533416A Active JP7704751B2 (ja) | 2019-12-06 | 2020-12-04 | 再発性および／または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用 |
| JP2025106921A Pending JP2025138745A (ja) | 2019-12-06 | 2025-06-25 | 再発性および／または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025106921A Pending JP2025138745A (ja) | 2019-12-06 | 2025-06-25 | 再発性および／または不応性の多発性骨髄腫の処置のためのイサツキシマブの使用 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20210171653A1 (https=) |
| EP (1) | EP4069740A1 (https=) |
| JP (2) | JP7704751B2 (https=) |
| KR (1) | KR20220159948A (https=) |
| CN (1) | CN115698065A (https=) |
| AU (1) | AU2020398655A1 (https=) |
| BR (1) | BR112022010907A2 (https=) |
| CA (1) | CA3164026A1 (https=) |
| CO (1) | CO2022009433A2 (https=) |
| IL (1) | IL293615A (https=) |
| MX (1) | MX2022006883A (https=) |
| TW (1) | TWI887310B (https=) |
| WO (1) | WO2021113754A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3258344A1 (en) | 2022-06-07 | 2023-12-14 | Actinium Pharmaceuticals, Inc. | CHELETARIANS AND BIFUNCTIONAL CONJUGATES |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1914242A1 (en) | 2006-10-19 | 2008-04-23 | Sanofi-Aventis | Novel anti-CD38 antibodies for the treatment of cancer |
| SG10201913777XA (en) * | 2013-03-13 | 2020-03-30 | Sanofi Sa | Compositions comprising anti-cd38 antibodies and carfilzomib |
| US20150118251A1 (en) * | 2013-10-31 | 2015-04-30 | Sanofi | Specific anti-cd38 antibodies for treating human cancers |
| MA50514A (fr) * | 2017-10-31 | 2020-09-09 | Janssen Biotech Inc | Méthodes de traitement du myélome multiple à haut risque |
-
2020
- 2020-12-04 CN CN202080095185.2A patent/CN115698065A/zh active Pending
- 2020-12-04 KR KR1020227023019A patent/KR20220159948A/ko active Pending
- 2020-12-04 EP EP20829459.5A patent/EP4069740A1/en active Pending
- 2020-12-04 WO PCT/US2020/063468 patent/WO2021113754A1/en not_active Ceased
- 2020-12-04 TW TW109142973A patent/TWI887310B/zh active
- 2020-12-04 US US17/112,862 patent/US20210171653A1/en active Pending
- 2020-12-04 JP JP2022533416A patent/JP7704751B2/ja active Active
- 2020-12-04 AU AU2020398655A patent/AU2020398655A1/en active Pending
- 2020-12-04 MX MX2022006883A patent/MX2022006883A/es unknown
- 2020-12-04 IL IL293615A patent/IL293615A/en unknown
- 2020-12-04 BR BR112022010907A patent/BR112022010907A2/pt unknown
- 2020-12-04 CA CA3164026A patent/CA3164026A1/en active Pending
-
2022
- 2022-07-05 CO CONC2022/0009433A patent/CO2022009433A2/es unknown
-
2025
- 2025-06-25 JP JP2025106921A patent/JP2025138745A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022518060A5 (https=) | ||
| JP2023123627A5 (https=) | ||
| JP2021502961A5 (https=) | ||
| JP2021523122A5 (https=) | ||
| CA2707400A1 (en) | Method for treating bone fracture with anti-sclerostin antibodies | |
| JP2018507220A5 (https=) | ||
| JP2024540054A5 (https=) | ||
| JP2021528438A5 (https=) | ||
| JP2022532356A5 (https=) | ||
| JP2023501375A5 (https=) | ||
| JP2022528721A5 (https=) | ||
| JP2024534602A5 (https=) | ||
| JP2023520771A5 (https=) | ||
| JP2019524820A5 (https=) | ||
| JP2023515675A5 (https=) | ||
| JP2023505219A5 (https=) | ||
| JP2021523138A5 (https=) | ||
| JP2019534251A5 (https=) | ||
| JP2020521490A5 (https=) | ||
| JP2023506779A5 (https=) | ||
| JP2022529266A5 (https=) | ||
| JP2024528877A5 (https=) | ||
| JP2022514561A5 (https=) | ||
| JP2021529766A5 (https=) | ||
| RU2022118184A (ru) | Применение изатуксимаба для лечения рецидивирующей и/или рефрактерной множественной миеломы |